Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study

NCT: NCT04393961 · WITHDRAWN

NCT IDNCT04393961
StatusWITHDRAWN
Start Date2020-04-05
Completion2020-08-29
SponsorProofPilot (INDUSTRY)
First posted
Last updated

Brief Summary

Radish Health and ProofPilot in coordination with Sanesco are running this study to help establish whether the Premier Biotech COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma Authorized for distribution under emergency use authorization - though not yet FDA reviewed) can be conducted effectively at home to detect COVID-19 antibodies among individuals who have tested positive, or suspect they have previous contracted from COVID-19 and recovered. The study also aims to examine how the results of those tests change social-distancing behaviors and general anxiety over 8 weeks post-test.

Frequently Asked Questions

What is At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study?

At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study is a clinical trial registered under NCT04393961. Current status: WITHDRAWN.

What is the status of NCT04393961?

The current status of NCT04393961 (At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study) is: WITHDRAWN.

When did At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study start?

At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study started on 2020-04-05.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.